Literature DB >> 32845355

T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Takashi Akiyoshi1, Osamu Gotoh2, Norio Tanaka2, Kazuma Kiyotani2, Noriko Yamamoto3, Masashi Ueno4, Yosuke Fukunaga5, Seiichi Mori6.   

Abstract

Emerging evidence suggests that an increased density of pre-treatment CD8+ tumor-infiltrating lymphocytes (TILs) is associated with good response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. However, the significance of T-cell complexity in the clinical setting remains unknown. High-throughput T-cell receptor (TCR) β sequencing was applied to quantify the TCR repertoire of pre-treatment biopsies from 67 patients with advanced rectal cancer receiving preoperative CRT. Diversity index was used to represent the complexity of the TCR repertoire in a tumor. Pre-treatment CD8+ TIL densities were assessed by immunohistochemistry. Changes in TCR repertoire before and after CRT were also analysed in 23 patients. Diversity indices were significantly higher for good responders than for non-responders (P = 0.031). The multivariate analysis revealed that both CD8+ TIL density and TCR diversity index were independently associated with good response to CRT (P < 0.001 and P = 0.049, respectively). Patients who were high for both CD8+ TIL density and TCR diversity (double-high) had markedly better responses to CRT than double-low patients (84.2% vs 16.7%, P < 0.0001). Larger changes in TCR repertoires before and after CRT were correlated with better recurrence-free survival (P = 0.027). The complexity and dynamic change in the TCR repertoire might serve as a useful indicator of response to CRT in combination with CD8+ TIL density in patients with rectal cancer.

Entities:  

Keywords:  Chemoradiotherapy; Rectal cancer; T-cell receptor repertoire; Tumor-infiltrating lymphocyte

Year:  2020        PMID: 32845355     DOI: 10.1007/s00262-020-02705-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  1 in total

1.  p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.

Authors:  F R Spitz; G G Giacco; K Hess; L Larry; T A Rich; N Janjan; K R Cleary; J M Skibber
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

  1 in total
  10 in total

1.  ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.

Authors:  Rodney Cheng-En Hsieh; Sunil Krishnan; Ren-Chin Wu; Akash R Boda; Arthur Liu; Michelle Winkler; Wen-Hao Hsu; Steven Hsesheng Lin; Mien-Chie Hung; Li-Chuan Chan; Krithikaa Rajkumar Bhanu; Anupallavi Srinivasamani; Ricardo Alexandre De Azevedo; Yung-Chih Chou; Ronald A DePinho; Matthew Gubin; Eduardo Vilar; Chao Hsien Chen; Ravaen Slay; Priyamvada Jayaprakash; Shweta Mahendra Hegde; Genevieve Hartley; Spencer T Lea; Rishika Prasad; Brittany Morrow; Coline Agnes Couillault; Madeline Steiner; Chun-Chieh Wang; Bhanu Prasad Venkatesulu; Cullen Taniguchi; Yon Son Betty Kim; Junjie Chen; Nils-Petter Rudqvist; Michael A Curran
Journal:  Sci Immunol       Date:  2022-06-10

Review 2.  Biomarkers of Favorable vs. Unfavorable Responses in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.

Authors:  Hsin-Hua Lee; Chien-Hung Chen; Yu-Hsiang Huang; Cheng-Han Chiang; Ming-Yii Huang
Journal:  Cells       Date:  2022-05-11       Impact factor: 7.666

3.  Role of adjuvant chemotherapy in patients with localized, undifferentiated pleomorphic sarcoma of soft tissue: a population-based cohort study.

Authors:  Hiroshi Kobayashi; Liuzhe Zhang; Toshihide Hirai; Yusuke Tsuda; Masachika Ikegami; Sakae Tanaka
Journal:  Int J Clin Oncol       Date:  2022-01-22       Impact factor: 3.402

4.  Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density.

Authors:  Yao Xu; Xiaoying Lou; Yanting Liang; Zhenhui Li; Shenyan Zhang; Shangqing Yang; Qicong Chen; Zeyan Xu; Minning Zhao; Ke Zhao; Zaiyi Liu
Journal:  J Inflamm Res       Date:  2021-11-10

5.  Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yuqin Yang; Wenjing Tian; Liqian Su; Peiqiu Li; Xiaohua Gong; Lu Shi; Qingling Zhang; Bin Zhao; Hong Zhao
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

Review 6.  Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.

Authors:  Moying Li; Qiyun Xiao; Nachiyappan Venkatachalam; Ralf-Dieter Hofheinz; Marlon R Veldwijk; Carsten Herskind; Matthias P Ebert; Tianzuo Zhan
Journal:  Ther Adv Med Oncol       Date:  2022-02-21       Impact factor: 8.168

7.  Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy.

Authors:  Hanyang Wang; Dengbo Ji; Huifang Tian; Zhaoya Gao; Can Song; Jinying Jia; Xinxin Cui; Lijun Zhong; Jing Shen; Jin Gu
Journal:  BMC Cancer       Date:  2022-08-09       Impact factor: 4.638

8.  Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response.

Authors:  Yu-Ming Huang; Hsi-Hsien Hsu; Chien-Kuo Liu; Ching-Kuo Yang; Po-Li Tsai; Tzu-Yin Tang; Shih-Ming Hsu; Yu-Jen Chen
Journal:  J Clin Med       Date:  2022-08-23       Impact factor: 4.964

Review 9.  Immunogenomics in personalized cancer treatments.

Authors:  Kazuma Kiyotani; Yujiro Toyoshima; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2021-06-30       Impact factor: 3.172

Review 10.  Personalized immunotherapy in cancer precision medicine.

Authors:  Kazuma Kiyotani; Yujiro Toyoshima; Yusuke Nakamura
Journal:  Cancer Biol Med       Date:  2021-08-09       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.